Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves new pain medicine
What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is
22h
on MSN
What is Non-Opioid Pain Medication? Journavx Approved by FDA
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
2d
on MSN
FDA Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...
PBS
6d
The FDA banned Red 3 food coloring. A scientist explains the dye’s history and health risks
Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S.
Medical News Today
5d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
6d
The FDA pulls key DEI initiative for cancer studies from its website
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback